PF-04958242 clinical trials
Also written PF-04958242 and BIIB104.
- studies test it
- 17
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses PF-04958242 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
17 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 0
Studies
Open first, then newest update. How each study uses PF-04958242 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)CompletedPhase 2BiogenNCT03745820Written as BIIB104How we know
- A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsCompletedPhase 1BiogenNCT05148481Written as BIIB104How we know
- A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy ParticipantsCompletedPhase 1BiogenNCT05152485Written as BIIB104 Reference FormulationHow we know
- Multiple Ascending Doses of PF-04958242 in Subjects With Stable SchizophreniaCompletedPhase 1BiogenNCT02332798Written as PF-04958242How we know
- Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsCompletedPhase 1BiogenNCT04079101Written as BIIB104How we know
- A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy ParticipantsCompletedPhase 1BiogenNCT04068532Written as BIIB104How we know
- A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy SubjectsCompletedPhase 1BiogenNCT02341482Written as PF-04958242How we know
- A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)TerminatedPhase 2BiogenNCT02855411Written as PF-04958242How we know
- Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy VolunteersCompletedPhase 1BiogenNCT02228395Written as PF-04958242How we know
- A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy SubjectsCompletedPhase 1BiogenNCT01365338Written as PF-04958242How we know
- First-in-Human Study of PF-04958242 in Healthy VolunteersCompletedPhase 1BiogenNCT01159483Written as PF-04958242How we know
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult VolunteersTerminatedPhase 1BiogenNCT01238679Written as PF-04958242How we know
- A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing LossCompletedPhase 1BiogenNCT01518920Written as PF-04958242How we know
- A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With SchizophreniaCompletedPhase 1BiogenNCT01518894Written as PF-04958242How we know
- Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution FormulationCompletedPhase 1BiogenNCT01646840Written as PF-04958242 capsuleHow we know
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy VolunteersCompletedPhase 1BiogenNCT01511510Written as PF-04958242How we know
- A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy VolunteersCompletedPhase 1BiogenNCT01749098Written as PF-04958242How we know
Codes
What other systems call PF-04958242 · ClinicalTrials.gg INT000305
- UNII (FDA) 9G1A824CC2PESAMPATORConfirmed FDA, Wikidata
- Wikidata Q27272515PF-04958242Confirmed FDA, Wikidata
- DrugBank DB11843One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9G1A824CC2 | PESAMPATOR | Confirmed FDA, Wikidata |
| Wikidata | Q27272515 | PF-04958242 | Confirmed FDA, Wikidata |
| DrugBank | DB11843 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.